Higher Upadacitinib Dose May Be Better for UC Maintenance
(MedPage Today) -- A higher daily dose of upadacitinib (Rinvoq) was associated with less severe disease and longer clinical remission for ulcerative colitis patients who responded to upadacitinib induction at 8 weeks, a post-hoc analysis of the... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - October 24, 2022 Category: Gastroenterology Source Type: news
New TREMFYA ® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2b QUASAR Induction Study 1 in adults with moderately to severely active ulcerative colitis (UC) with inadequate responses to previous treatments. The data presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting show an overall clinical response rate of approximately 80 percent in patients who were randomized to TREMFYA® (guselkumab).Clinical responsea at weeks 12 or 24 of the study was ultimately achieved by 80.2 percent of patients who w...
Source: Johnson and Johnson - October 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
About Half of Patients With IBD Have Zinc Deficiency
FRIDAY, Oct. 21, 2022 -- The prevalence of zinc deficiency is about 50 percent in inflammatory bowel disease (IBD) and is higher in patients with Crohn disease (CD) than those with ulcerative colitis (UC), according to a study published online Sept.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 21, 2022 Category: Pharmaceuticals Source Type: news
Should You Tell Your Boss You Have IBD? Plus More Tips for Coping at the Office
As the human resources director for family Destinations Guide, a website that offers kid-friendly vacation ideas, Bonnie Whitfield always makes sure employees feel comfortable disclosing their medical conditions so the company can provide accommodations. For Whitfield, it’s not just professional—it’s personal, because she has inflammatory bowel disease (IBD).
“Since I have IBD myself, and I’ve been through a few flare-ups at work, I know what it’s like to be in that situation,” she says. Employees are often trying to navigate not just the symptoms of a chronic illness, but also anx...
Source: TIME: Health - October 20, 2022 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized Gut health healthscienceclimate Source Type: news
Long-Term Xeljanz for UC; AGA Drops Obesity Drug Guidelines; PPIs & Cystic Fibrosis?
(MedPage Today) -- Health-related quality-of-life outcomes continued to be favorable with maintenance tofacitinib (Xeljanz) for ulcerative colitis (UC) during up to 6 years of follow-up, regardless of treatment history, responder status, or remission... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - October 20, 2022 Category: Gastroenterology Source Type: news
Johnson & Johnson Reports Q3 2022 Results
New Brunswick, N.J. (October 18, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2022. “Our third quarter performance demonstrates our continued strength and resilience across all three of our businesses,” said Joaquin Duato, Chief Executive Officer. “Through the ongoing efforts of our teams around the world, we continue to navigate the dynamic macroeconomic environment and remain focused on delivering transformative healthcare solutions. Looking ahead, I remain confident in our business and ability to continue advancing our innovative portfolio and pipeline.”OVERALL FINANCIAL ...
Source: Johnson and Johnson - October 18, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news
Eating More Unprocessed Foods Tied to Lower Risk of Crohn's Disease
(MedPage Today) -- Eating more unprocessed or minimally processed foods was linked to a lower risk of Crohn's disease, with no association seen for ulcerative colitis, according to data on participants in the European Prospective Investigation... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - October 14, 2022 Category: Primary Care Source Type: news
STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).1 Among all patients who had achieved clinical responsea with STELARA during induction, 64.9 percent were in symptomatic remissionb after 44 weeks of maintenance. At week 200 (four years), this proportion of patients was 55.2 percent; the majority (96.4 percen...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
Risk of Dementia in Patients With Inflammatory Bowel Disease Risk of Dementia in Patients With Inflammatory Bowel Disease
Do ulcerative colitis or Crohn ' s disease increase the risk of dementia?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 16, 2022 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
TREMFYA ®▼ (guselkumab) Demonstrates Higher Rates of Complete Skin Clearance with Earlier Treatment in Adults with Moderate to Severe Plaque Psoriasis in Phase 3b GUIDE Study
Beerse, Belgium, 8 September 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for TREMFYA®▼(guselkumab) from the ongoing Phase 3b GUIDE study, which is designed to understand the impact of early intervention and potential dosing interval flexibility on the long-term disease course in adult patients with moderate to severe plaque psoriasis (Pso). These new data demonstrated that “super responders”a to guselkumab who received every-16-week dosingb maintained disease control (absolute Psoriasis Area and Severity Index [PASI] score <3) at a rate that was non-inferior to ...
Source: Johnson and Johnson - September 8, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
First-in-Class Drug Brings Relief in Ulcerative Colitis
(MedPage Today) -- A first-in-class investigational agent offered symptom relief to patients with active moderate-to-severe ulcerative colitis (UC), according to a phase IIb randomized trial.
Among over 200 patients, those who received three different... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - September 7, 2022 Category: Gastroenterology Source Type: news
These Environmental Factors Increase the Risk of IBD
During the past 60 years, experts have documented a steep rise in the incidence of both ulcerative colitis and Crohn’s disease—the two medical conditions that make up most cases of inflammatory bowel disease (IBD). For decades, this rise was confined to North America, Western Europe, and other industrialized nations. While there’s some evidence that the rise in IBD has slowed down or even plateaued in those places, IBD is becoming increasingly common in newly industrialized countries in Asia and other parts of the world.
There’s no question that genetic factors play a part in a person’s risk f...
Source: TIME: Health - September 2, 2022 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Disease freelance healthscienceclimate Source Type: news
Researchers take aim at cancer drugs ’ toxic side effects
The patient was a success story, his advanced melanoma erased by a popular new cancer treatment. Known as immune checkpoint inhibitors, the drugs coax the immune system to seek and destroy cancer cells—and in this case, they “worked beautifully,” says Kerry Reynolds, an oncologist at Massachusetts General Hospital (MGH) who helped care for the man.
But about a month after an infusion, without a melanoma cell detectable in his body, the 64-year-old was admitted to the hospital, gravely ill. The drugs were sending his immune system into overdrive, wreaking havoc on his colon and nervous system.
Doctors strug...
Source: ScienceNOW - August 31, 2022 Category: Science Source Type: news
Now MS pills are used to ease the agony of ulcerative colitis
One patient to benefit from ozanimod is Albert Williamson-Taylor, a 63-year-old engineer from London. The father-of-four has suffered ulcerative colitis for 30 years. (Source: the Mail online | Health)
Source: the Mail online | Health - August 27, 2022 Category: Consumer Health News Source Type: news
